Cardiff Oncology (CRDF) 10-Q 7 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 05, 2014
Document and Entity Information	'	'
Entity Registrant Name	'Trovagene, Inc.	'
Entity Central Index Key	'0001213037	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	18,902,782
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$34,673,893	$25,836,937
Accounts receivable	59,910	78,994
Prepaid expenses and other assets	295,755	152,789
Total current assets	35,029,558	26,068,720
Property and equipment, net	817,024	750,565
Other assets	346,902	336,450
Total assets	36,193,484	27,155,735
Current liabilities:	'	'
Accounts payable	379,715	286,608
Accrued expenses	1,599,685	1,524,092
Current portion of long-term debt	'	198,166
Total current liabilities	1,979,400	2,008,866
Long-term debt, less current portion	14,702,866	322,998
Derivative financial instruments	2,181,883	4,431,871
Total liabilities	18,864,149	6,763,735
Commitments and contingencies (Note 9)	'	'
Stockholders' equity	'	'
Preferred stock, $0.001 par value, 20,000,000 shares authorized; 60,600 shares outstanding at June 30, 2014 and December 31, 2013; designated as Series A Convertible Preferred Stock with liquidation preference of $606,000 at June 30, 2014 and December 31, 2013	60	60
Common stock, $0.0001 par value, 150,000,000 shares authorized; 18,902,782 shares issued and outstanding at June 30, 2014 and December 31, 2013	1,890	1,890
Additional paid-in capital	88,648,577	87,433,460
Accumulated deficit	-71,321,192	-67,043,410
Total stockholders' equity	17,329,335	20,392,000
Total Liabilities and Stockholders' Equity	$36,193,484	$27,155,735

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
CONDENSED CONSOLIDATED BALANCE SHEETS	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares outstanding	60,600	60,600
Series A Convertible Preferred Stock, liquidation preference (in dollars)	$606,000	$606,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	18,902,782	18,902,782
Common stock, shares outstanding	18,902,782	18,902,782

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS	'	'	'	'
Royalty income	$45,628	$49,000	$156,581	$168,123
License fees	10,000	'	10,000	'
Total revenues	55,628	49,000	166,581	168,123
Costs and expenses:	'	'	'	'
Research and development	1,397,173	943,849	2,839,694	1,746,094
Selling and marketing	589,814	465,172	1,159,404	825,632
General and administrative	1,310,239	1,014,091	2,668,719	2,360,348
Total operating expenses	3,297,226	2,423,112	6,667,817	4,932,074
Loss from operations	-3,241,598	-2,374,112	-6,501,236	-4,763,951
Interest income	2,079	'	4,470	'
Interest expense	-54,714	-668	-64,210	-668
Gain on disposal of equipment	'	'	44,101	'
Change in fair value of derivative instruments-warrants	2,217,142	-2,895,310	2,249,988	-1,616,168
Net loss	-1,077,091	-5,270,090	-4,266,887	-6,380,787
Preferred stock dividend	-1,685	-9,385	-10,895	-15,270
Net loss attributable to common stockholders	($1,078,776)	($5,279,475)	($4,277,782)	($6,396,057)
Net loss per common share-basic and diluted (in dollars per share)	($0.06)	($0.34)	($0.23)	($0.41)
Weighted average shares outstanding - basic and diluted (in shares)	18,902,782	15,583,957	18,902,782	15,547,352

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Operating activities	'	'
Net loss	($4,266,887)	($6,380,787)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Net gain on disposal of fixed assets	-44,101	'
Depreciation and amortization	111,300	43,933
Stock based compensation expense	979,260	688,817
Stock and warrant issued in connection with consulting services	'	198,791
Change in fair value of financial instruments	-2,249,988	1,616,168
Changes in operating assets and liabilities:	'	'
Increase in other assets	-10,452	-168,531
Decrease in accounts receivable	19,084	111,880
Increase in prepaid expenses	-142,966	-104,676
Increase in accounts payable and accrued expenses	152,605	629,780
Net cash used in operating activities	-5,452,145	-3,364,625
Investing activities:	'	'
Capital expenditures, net	-133,658	-360,138
Net cash used in investing activities	-133,658	-360,138
Financing activities:	'	'
Proceeds from exercise of warrants	'	892,104
Net borrowings under debt agreements	14,422,759	315,168
Net cash provided by financing activities	14,422,759	1,207,272
Net change in cash and equivalents	8,836,956	-2,517,491
Cash and cash equivalents-Beginning of period	25,836,937	10,819,781
Cash and cash equivalents-End of period	34,673,893	8,302,290
Supplementary disclosure of cash flow activity:	'	'
Cash paid for taxes	2,400	7,650
Cash paid for interest	71,756	'
Supplemental disclosure of non-cash investing and financing activities:	'	'
Preferred stock dividends accrued	10,895	15,270
Warrants issued in connection with Loan and Security Agreement	$235,857	'

Business_Overview_Basis_of_Pre

Business Overview, Basis of Presentation and Liquidity	6 Months Ended
	Jun. 30, 2014
Business Overview, Basis of Presentation and Liquidity	'
Business Overview, Basis of Presentation and Liquidity	'
	1. Business Overview, Basis of Presentation and Liquidity
	Business Overview
	Trovagene, Inc. (“Trovagene” or the “Company”) is focused on developing and commercializing its precision cancer monitoring technology, which can inform oncologists and guide treatment decisions by determining a tumor’s mutational status and enabling oncologists to track therapeutic response and resistance over time.
	The Company is in the process of expanding the body of clinical evidence supporting its urine-based cell-free DNA mutation tracking platform through collaborations with major cancer treatment centers and integrated healthcare networks.  This year, Trovagene expects that the benefits of its precision cancer monitoring technology will become more apparent in terms of its clinical utility and impact on patient outcomes.  The Company’s intellectual property estate protecting its technology includes methods of extracting, purifying, preparing, and detecting cell-free DNA and RNA mutations in both blood and urine.
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements of Trovagene, which include its wholly owned subsidiaries Xenomics, Inc., a California corporation, Xenomics Europa Ltd, (an inactive subsidiary formed in the United Kingdom and liquidated) and Etherogen, Inc., a Delaware corporation, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated. Certain items in the comparable prior period’s financial statements have been reclassified to conform to the current period’s presentation.  The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements as of December 31, 2013 and 2012 and for each of the three years ended December 31, 2013 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2014.  The accompanying condensed consolidated financial statements have been prepared by the Company without audit.  In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at June 30, 2014, and for all periods presented herein, have been made.  The results of operations for the periods ended June 30, 2014 and 2013 are not necessarily indicative of the operating results for the full year.
	In June 2014, the Financial Accounting Standards Board (the FASB) issued an accounting standards update that removes the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP.  In addition, the amendments eliminate the requirements for development stage entities to: (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity,  (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.  The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2014, with an option for early adoption. The Company elected early adoption, and does not believe the adoption of the standard had a material impact on our financial position, results of operations or related financial statement disclosures.
	Liquidity
	Trovagene’s condensed consolidated financial statements as of June 30, 2014 have been prepared under the assumption that Trovagene will continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional equity or debt financing, attain further operating efficiencies and, ultimately, to generate additional revenue.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.  Based on current plans the Company will be required to raise additional capital within the next twenty-four months to complete the development and commercialization of current product candidates and to continue to fund operations at its current projected cash expenditure levels.
	Cash used in operating activities was $5,452,145 and $3,364,625, for the six months ended June 30, 2014 and 2013, respectively.  During the six months ended June 30, 2014 and 2013, the Company incurred a net loss of $4,266,887 and $6,380,787, respectively.
	To date, Trovagene’s sources of cash have been primarily related to financing activities, including the sale of debt and equity securities, debt borrowings and proceeds from exercise of warrants and options.  During the six months ended June 30, 2014, cash provided by financing activities was $14,422,759 and resulted from debt borrowings, while in the same period of the prior year, $1,207,272 was provided by debt borrowings and the exercise of warrants.  The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution.  Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct its business.
	If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of its product candidates. The Company may also be required to:
		·	Seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and
		·	Relinquish licenses or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize themselves, on unfavorable terms.
	The Company has approximately $33.6 million of cash and cash equivalents at July 31, 2014.

Net_Loss_Per_Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2014
Net Loss Per Share	'
Net Loss Per Share	'
	2. Net Loss Per Share
	Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, for all periods presented. In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period.  In a period where there is a net loss position, diluted weighted-average shares are the same as basic weighted-average shares.  Shares used in calculating basic and diluted net loss per common share for the six months ended June 30 exclude as antidilutive the following share equivalents:
		June 30,
		2014	2013
	Options to purchase Common Stock	3,897,249	4,012,710
	Warrants to purchase Common stock	6,302,286	6,796,491
	Series A Convertible Preferred Stock	63,125	81,354
		10,262,660	10,890,555

Accounting_for_ShareBased_Paym

Accounting for Share-Based Payments	6 Months Ended
	Jun. 30, 2014
Accounting for Share-Based Payments	'
Accounting for Share-Based Payments	'
	3.          Accounting for Share-Based Payments
	Stock Options
	ASC Topic 718 “Compensation—Stock Compensation” requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant.  The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award.  ASC Topic 718 did not change the way Trovagene accounts for non-employee stock-based compensation.  Trovagene accounts for shares of common stock, stock options and warrants issued to non-employees based on the fair value of the stock, stock option or warrant, if that value is more reliably measurable than the fair value of the consideration or services received. The Company accounts for stock options issued and vesting to non-employees in accordance with ASC Topic 505-50  “ Equity-Based Payment to Non-Employees” whereas the value of the stock compensation is based upon the measurement date as determined at either: a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Accordingly the fair value of these options is being “marked to market” quarterly until the measurement date is determined.
	Stock-based compensation expense related to Trovagene options have been recognized in operating results as follow:
		Three Months						Six Months
		Ended June 30,						Ended June 30,
		2014			2013			2014		2013
	Included in research and development expense	$	166,019		$	179,892		$	355,653	$	302,209
	Included in selling and marketing expense	29,989			24,085			52,670		45,802
	Included in general and administrative expense	223,479			143,365			570,937		340,806
	Total stock-based compensation expense	$	419,487		$	347,342		$	979,260	$	688,817
	The unrecognized compensation cost related to non-vested stock options outstanding at June 30, 2014 and 2013, net of expected forfeitures, was $3,364,401 and $3,708,208, respectively, both to be recognized over a weighted-average remaining vesting period of approximately three years.  The weighted average remaining contractual term of outstanding options as of June 30, 2014 was approximately seven years.
	The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the following periods indicated:
		Six Months Ended
		June 30,
		2014		2013
	Risk-free interest rate	1.46-1.69	%	0.74-1.48	%
	Dividend yield	0	%	0	%
	Expected volatility	74-84	%	97-100	%
	Expected term (in years)	5.0 yrs.		5.0 yrs.
	A summary of stock option activity and of changes in stock options outstanding under the Trovagene Stock Option Plan is presented below:
		Total Options		Weighted Average			Intrinsic
				Exercise Price			Value
				Per Share
	Balance outstanding, December 31, 2013	4,287,545		$	5.18
	Granted	281,870
	Forfeited	(672,166	)
	Balance outstanding, June 30, 2014	3,897,249		$	4.79		$	929,688
	Exercisable at June 30, 2014	2,000,679		$	4.88		$	576,626
	The Trovagene Stock Option Plan expired on June 24, 2014.  The Trovagene Inc. 2014 Equity Incentive Plan, authorizing up to 2,500,000 shares of common stock for issuance under the Plan, was proposed and is pending approval at the September 17, 2014 Annual Shareholders’ Meeting.
	Warrants
	A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:
		Total Warrants		Weighted Average			Weighted Average
				Exercise Price			Remaining Contractual
				Per Share			Term
	Balance outstanding, December 31, 2013	6,233,483		$	3.87		4.5 years
	Granted	85,470		$	3.51
	Forfeited	(16,667	)	$	10.8
	Balance outstanding, June 30, 2014	6,302,286		$	3.84		$	4.1 years

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity	'
Stockholders' Equity	'
	4.Stockholders’ Equity
	Common Stock
	On January 25, 2013, the Company filed a Form S-3 Registration Statement to offer and sell in one or more offerings, any combination of common stock, preferred stock, warrants, or units having an aggregate initial offering price not exceeding $150,000,000.  The preferred stock, warrants, and units may be convertible or exercisable or exchangeable for common stock or preferred stock or other Trovagene securities.  This form was declared effective on February 4, 2013.  In addition, in connection with the Form S-3, the Company entered into an agreement with Cantor Fitzgerald & Co. (“Agent”) on January 25, 2013 to issue and sell up to $30,000,000 of shares of common stock through them.  As payment for its services, the Agent is entitled to a 3% commission on gross proceeds.  There were no sales of common stock during the six months ended June 30, 2014.

Asset_Purchase_Agreement

Asset Purchase Agreement	6 Months Ended
	Jun. 30, 2014
Asset Purchase Agreement	'
Asset Purchase Agreement	'
	5. Asset Purchase Agreement
	On February 1, 2012, the Company entered into an asset purchase agreement with MultiGen Diagnostics, Inc.  The Company determined that the acquired asset did not meet the definition of a business, as defined in ASC 805, Business Combinations and was accounted for under ASC 350, Intangibles- Goodwill and Other .  In connection with the acquisition, the Company issued 125,000 shares of restricted common stock to MultiGen.  In addition, up to an additional $3.7 million may be paid in a combination of common stock and cash to MultiGen upon the achievement of specific sales and earnings targets.  In addition, in connection with the acquisition, the Company entered into a Reagent Supply Agreement dated as of February 1, 2012 pursuant to which MultiGen will supply and deliver reagents to be used in connection with a Clinical Laboratory Improvement Amendment (CLIA) laboratory.  The total purchase consideration was determined to be $187,500 which was paid in the Company’s common stock and allocated to an indefinite lived intangible asset related to the CLIA license.
	Under ASC Topic 805, Business Combinations, the Company was required to assess the fair value of the assets acquired and the contingent consideration at the date of acquisition.  Therefore, the Company assessed the fair value of the assets purchased and concluded that the purchase price would be allocated entirely to one intangible asset, a CLIA license.  The contingent consideration of the $3.7 million milestone was determined to have no fair value by applying a weighted average probability on the achievement of the milestones developed during the valuation process.  The Company assesses the fair value of the contingent consideration at each quarter and makes adjustments as necessary until the milestone dates have expired.  As of June 30, 2014, no adjustments to the fair value of the contingent consideration have been necessary, and therefore the fair value of the contingent consideration remains unchanged.

Derivative_Financial_Instrumen

Derivative Financial Instruments - Warrants	6 Months Ended
	Jun. 30, 2014
Derivative Financial Instruments - Warrants	'
Derivative Financial Instruments - Warrants	'
	6.  Derivative Financial Instruments - Warrants
	The Company follows the provisions of ASC Topic 815-40, “Derivatives and Hedging: Contracts in Entity’s Own Equity” (“ASC Topic 815-40”) for its derivative instruments.   ASC Topic 815-40 clarifies the determination of whether an instrument issued by an entity (or an embedded feature in the instrument) is indexed to an entity’s own stock, which would qualify as a scope exception under ASC Topic 815-10.
	Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Trovagene has determined that the warrants issued in connection with certain of its debentures must be recorded as derivative liabilities.  Accordingly the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant changes in fair value is being recorded in the Company’s condensed consolidated statement of operations.
	The Company estimates the fair value of the warrants issued in connection with certain of its debentures using the Black-Scholes model in order to determine the associated derivative instrument liability and change in fair value described above.  The following range of assumptions was used to determine the fair value of the warrants during the periods indicated:
		Six Months Ended
		June 30,
		2014			2013
	Estimated fair value of Trovagene common stock	$	3.50-$5.73		$	6.26-6.99
	Expected warrant term	4.5-4.8 years			4 months – 5.8 years
	Risk-free interest rate	1.62-1.73%			0.04-1.41%
	Expected volatility	74-83%			97-100%
	Dividend yield	0%			0%
	The following table sets forth the components of changes in the Company’s derivative financial instruments liability balance, valued using the Black-Scholes option pricing method, for the periods indicated:
	Date	Description		Warrants		Derivative
						Instrument
						Liability
	December 31, 2013	Balance of derivative financial instruments liability		1,013,961		$	4,431,871
		Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations		—		(2,249,988		)
	June 30, 2014	Balance of derivative financial instruments liability		1,013,961		$	2,181,883

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements	'
Fair Value Measurements	'
	7. Fair Value Measurements
	Fair value of financial instruments
	The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of June 30, 2014 and December 31, 2013:
			Fair Value Measurements at
			June 30, 2014
			Quoted Prices		Significant			Significant		Total
			in Active		Other			Unobservable
			Markets for		Observable			Inputs
			Identical Assets		Inputs			(Level 3)
			and Liabilities		(Level 2)
			(Level 1)
	Assets:
	Money market fund (1)		$	20,181,958	$	—		$	—	$	20,181,958
	Total Assets		$	20,181,958	$	—		$	—	$	20,181,958
	Liabilities:
	Derivative liabilities related to warrants		—		$	—		$	2,181,883	$	2,181,883
	Total Liabilities		$	—	$	—		$	2,181,883	$	2,181,883
			Fair Value Measurements at
			December 31, 2013
			Quoted Prices		Significant			Significant		Total
			in Active		Other			Unobservable
			Markets for		Observable			Inputs
			Identical Assets		Inputs			(Level 3)
			and Liabilities		(Level 2)
			(Level 1)
	Assets:
	Money market fund (1)		$	25,703,330	$	—		$	—	$	25,703,330
	Total Assets		$	25,703,330	$	—		$	—	$	25,703,330
	Liabilities:
	Derivative liabilities related to warrants		—		$	—		$	4,431,871	$	4,431,871
	Total Liabilities		$	—	$	—		$	4,431,871	$	4,431,871
		-1		Included as a component of cash and cash equivalents on the accompanying condensed consolidated balance sheets.
	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2014:
	Description		Balance at		Unrealized			Balance at
			December 31,		Gain			June 30,
			2013					2014
	Derivative liabilities related to Warrants		$	4,431,871	$	(2,249,988	)	$	2,181,883
	The unrealized gain on the derivative liabilities is recorded as a change in fair value of derivative liabilities in the Company’s condensed consolidated statement of operations.  A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40.  At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

Debt

Debt	6 Months Ended
	Jun. 30, 2014
Debt	'
Debt	'
	8. Debt
	Equipment Line of Credit
	In June 2013, the Company entered into a Loan and Security Agreement (“Equipment Line of Credit”) with Silicon Valley Bank that provided for cash borrowings for equipment of up to $1.0 million, secured by the equipment financed.  Under the terms of the agreement, interest was the greater of 5% or 4.6% above the U.S. Treasury Note as of the date of each borrowing.  Interest only payments were due on borrowings through December 31, 2013, with both interest and principal payments commencing in January 2014.  Any equipment advances after December 31, 2013 were subject to principal and interest payments immediately over a 30 month period following the advance.  In June 2014, the equipment loan was paid in full, the Company had no further obligations thereunder, and the bank released its security interest in such assets.
	The Company recorded approximately $61,000 in interest expense related to the Equipment Line of Credit during the six months ended June 30, 2014.
	Loan and Security Agreement
	In June 2014, the Company entered into a $15,000,000 loan and security agreement with two banks pursuant to which the lenders provided the Company a term loan, which was funded at closing. The interest rate on such loan is 7.07% per annum.  The Company will make interest only payments on the outstanding amount of the loan on a monthly basis through July 2015, after which equal monthly payments of principal and interest are due until the loan maturity date of July 1, 2018.  The loan is secured by a security interest in all of the Company’s assets except intellectual property, which is subject to a negative pledge. In connection with the loan, the lenders received a warrant to purchase an aggregate 85,470 shares of the Company’s common stock at an exercise price of $3.51 per share exercisable for ten years from the date of issuance.  The original value of the warrants, totaling $235,857, was recorded as debt discount and additional paid-in capital.
	At the Company’s option, it may prepay all of the outstanding principal balance, subject to certain pre-payment fees ranging from 1% to 3% of the prepayment amount.  In the event of a final payment of the loans under the loan agreement, either in the event of repayment of the loan at maturity or upon any prepayment, the Company is obligated to pay the amortized portion of the final fee of $1,050,000.
	The Company is also subject to certain affirmative and negative covenants under the loan agreement, including limitations on its ability to: undergo certain change of control events; convey, sell, lease, license, transfer or otherwise dispose of any equipment financed by loans under the loan agreement; create, incur, assume, guarantee or be liable with respect to indebtedness, subject to certain exceptions; grant liens on any equipment financed under the loan agreement; and make or permit any payment on specified subordinated debt.  In addition, under the loan agreement, subject to certain exceptions, the Company is required to maintain with the lender its primary operating, other deposit and securities accounts.
	Long-term debt and unamortized discount balances are as follows:
	Balance at December 31, 2013	$	—
	Face value of term loan	15,000,000
	Fair value of warrants and loan costs	(297,134		)
	Accretion of debt discount	—
	Balance at June 30, 2014	$	14,702,866
	Future minimum payments under the loan and security agreement are as follows:
	Year Ending December 31,
	2014	$	441,875
	2015	2,936,808
	2016	5,563,640
	2017	5,563,640
	2018	4,295,457
	Total future minimum payments	18,801,420
	Unamortized interest	(3,801,420		)
	Debt discount	(297,134		)
	Total minimum payment	14,702,866
	Current portion	—
	Long-term debt	$	14,702,866
	The Company recorded approximately $3,000 in interest expense related to the Loan and Security Agreement during the six months ended June 30, 2014.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies.	'
Commitments and Contingencies	'
	9. Commitments and Contingencies
	Executive and Consulting Agreements
	The Company has contracted with various consultants and third parties, including the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”).  The executive agreements with the CEO and CFO provide for severance payments.
	Lease Agreement
	The Company leases approximately 8,300 square feet of office space at a monthly rental rate of approximately $18,300 to $20,000 during the remaining term of the lease, through December 2017.  Effective May 14, 2014, the Company entered into the 5th amendment of its lease (the “Agreement”), that will increase the leased space by 4,751 square feet and increase the monthly rent by approximately $10,500 per month, commencing with occupation of the new space, which is expected to occur in the fourth quarter of 2014.
	Research and Development Agreements
	During 2012, the Company entered into research agreements with University of Texas MD Anderson Cancer Center (“MDACC”) to provide samples and evaluate methods used by the Company in identification of pancreatic cancer mutations, as well as to measure the degree of concordance between results of cell-free DNA mutations analysis from urine samples and tumor tissue.  During 2013, the agreements were amended to increase the scope of the agreements.  Under these agreements, the Company has committed to pay approximately $266,000 for the services performed by MDACC.  As of June 30, 2014, the Company has incurred and recorded approximately $204,000 of research and development expenses related to these agreements.
	In April 2013, the Company entered into a research and development agreement with PerkinElmer Health Sciences, Inc. (“PerkinElmer”) pursuant to which the Company will design an assay, based on the Company’s urine-based cell-free molecular diagnostic technology, to determine the risk for developing hepatocellular carcinoma.   A notice of termination was received in March 2014 terminating the agreement.  No further commitments exist from either party.   The Company had recognized milestone payments received from PerkinElmer as a reduction in research and development costs as the services were performed.  Amounts received in advance of services performed were recorded as accrued liabilities until the services for which the payment had been received were performed.  Through the date of termination of the agreement, the Company had received milestone payments of approximately $90,000 and incurred and recorded approximately $90,000 of research and development costs.
	In June 2013, the Company entered into a research agreement with Illumina, Inc. (“Illumina”) pursuant to which the parties will work together to evaluate the potential for integrating the Company’s transrenal technology for isolating, extracting and genetic analysis of nucleic acids from urine with Illumina’s genetic analysis sequencing technology (the “Research Plan”).  The parties have agreed that all results and reagents from the Research Plan will be shared between the parties.  The agreement will terminate upon the earlier of 30 days after completion of the research plan or the one year anniversary of the agreement unless extended by mutual written agreement.
	In August 2013, the Company entered into a clinical trial agreement with the University of Southern California (“USC”), pursuant to which USC will provide the principal investigator and conduct the clinical trial related to the genetic characterization of metastatic colorectal cancers.  Under the agreement, the Company may pay USC approximately $232,000 for services provided. Through June 30, 2014 the Company has incurred and recorded approximately $5,000 of research and development expense related to this agreement.
	In December 2013, the Company entered into a clinical trial agreement with US Oncology Research LLC (“USOR”), pursuant to which USOR will provide the principal investigator and conduct the clinical trial related to the examining the utility of transrenal quantitative KRAS testing in disease monitoring in patients with metastatic pancreatic cancer.  Under the agreement, the Company may pay USOR approximately $270,000 for services provided.  As of June 30, 2014 the Company has incurred and recorded approximately $32,000 of research and development expense related to this agreement.
	On May 8, 2014, the Company entered into a Patent Assignment and License Agreement, effective as of April 23, 2014, with GenSignia IP Ltd., a United Kingdom company, pursuant to which the Company assigned all of its miRNA patents, including methods of using miRNA for detection of in vivo cell death and detecting cell-free miRNA in urine and blood.  Concurrent with the assignment, GenSignia granted to the Company an exclusive, world-wide, royalty-free, fully paid, perpetual license under the transferred patents in the urine field.  Pursuant to the agreement, GenSignia will pay the Company a low single digit royalty on net sales and will pay an aggregate $6.5 million in milestone payments upon the achievement of up to $150 million in net sales.  GenSignia shall be responsible for the preparation, filing and maintenance of all patents under the agreement.  Antonius Schuh, the Company’s CEO and a director, is a director of GenSignia.  Dr. Schuh did not participate in any negotiations with respect to the agreement and recused himself from any director vote in connection with the agreement.  As of June 30, 2014, the Company had recorded $10,000 in license fee revenue related to the agreement.  No costs or expenses have been incurred through June 30, 2014.

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Net Loss Per Share	'
Schedule of antidilutive securities excluded from the calculation of basic and diluted loss per share	'
		June 30,
		2014	2013
	Options to purchase Common Stock	3,897,249	4,012,710
	Warrants to purchase Common stock	6,302,286	6,796,491
	Series A Convertible Preferred Stock	63,125	81,354
		10,262,660	10,890,555

Accounting_for_ShareBased_Paym1

Accounting for Share-Based Payments (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting for Share-Based Payments	'
Schedule of stock-based compensation expense	'
		Three Months						Six Months
		Ended June 30,						Ended June 30,
		2014			2013			2014		2013
	Included in research and development expense	$	166,019		$	179,892		$	355,653	$	302,209
	Included in selling and marketing expense	29,989			24,085			52,670		45,802
	Included in general and administrative expense	223,479			143,365			570,937		340,806
	Total stock-based compensation expense	$	419,487		$	347,342		$	979,260	$	688,817
Schedule of assumptions to estimate fair value of stock option awards	'
		Six Months Ended
		June 30,
		2014		2013
	Risk-free interest rate	1.46-1.69	%	0.74-1.48	%
	Dividend yield	0	%	0	%
	Expected volatility	74-84	%	97-100	%
	Expected term (in years)	5.0 yrs.		5.0 yrs.
Summary of stock option activity and of changes in stock options outstanding	'
		Total Options		Weighted Average			Intrinsic
				Exercise Price			Value
				Per Share
	Balance outstanding, December 31, 2013	4,287,545		$	5.18
	Granted	281,870
	Forfeited	(672,166	)
	Balance outstanding, June 30, 2014	3,897,249		$	4.79		$	929,688
	Exercisable at June 30, 2014	2,000,679		$	4.88		$	576,626
Summary of warrant activity and changes in warrants outstanding	'
		Total Warrants		Weighted Average			Weighted Average
				Exercise Price			Remaining Contractual
				Per Share			Term
	Balance outstanding, December 31, 2013	6,233,483		$	3.87		4.5 years
	Granted	85,470		$	3.51
	Forfeited	(16,667	)	$	10.8
	Balance outstanding, June 30, 2014	6,302,286		$	3.84		$	4.1 years

Derivative_Financial_Instrumen1

Derivative Financial Instruments - Warrants (Tables) (Black Scholes Option Pricing Method [Member])	6 Months Ended
	Jun. 30, 2014
Black Scholes Option Pricing Method [Member]	'
Derivative financial instruments	'
Schedule of assumptions used to determine the fair value of the warrants	'
		Six Months Ended
		June 30,
		2014			2013
	Estimated fair value of Trovagene common stock	$	3.50-$5.73		$	6.26-6.99
	Expected warrant term	4.5-4.8 years			4 months – 5.8 years
	Risk-free interest rate	1.62-1.73%			0.04-1.41%
	Expected volatility	74-83%			97-100%
	Dividend yield	0%			0%
Schedule of components of changes in the Company's derivative financial instruments liability balance	'
	Date	Description		Warrants		Derivative
						Instrument
						Liability
	December 31, 2013	Balance of derivative financial instruments liability		1,013,961		$	4,431,871
		Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations		—		(2,249,988		)
	June 30, 2014	Balance of derivative financial instruments liability		1,013,961		$	2,181,883

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements	'
Schedule of the Company's assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy	'
		Fair Value Measurements at
		June 30, 2014
		Quoted Prices		Significant			Significant		Total
		in Active		Other			Unobservable
		Markets for		Observable			Inputs
		Identical Assets		Inputs			(Level 3)
		and Liabilities		(Level 2)
		(Level 1)
	Assets:
	Money market fund (1)	$	20,181,958	$	—		$	—	$	20,181,958
	Total Assets	$	20,181,958	$	—		$	—	$	20,181,958
	Liabilities:
	Derivative liabilities related to warrants	—		$	—		$	2,181,883	$	2,181,883
	Total Liabilities	$	—	$	—		$	2,181,883	$	2,181,883
		Fair Value Measurements at
		December 31, 2013
		Quoted Prices		Significant			Significant		Total
		in Active		Other			Unobservable
		Markets for		Observable			Inputs
		Identical Assets		Inputs			(Level 3)
		and Liabilities		(Level 2)
		(Level 1)
	Assets:
	Money market fund (1)	$	25,703,330	$	—		$	—	$	25,703,330
	Total Assets	$	25,703,330	$	—		$	—	$	25,703,330
	Liabilities:
	Derivative liabilities related to warrants	—		$	—		$	4,431,871	$	4,431,871
	Total Liabilities	$	—	$	—		$	4,431,871	$	4,431,871
	(1)Included as a component of cash and cash equivalents on the accompanying condensed consolidated balance sheets.
Schedule of changes in the fair value of the Company's Level 3 liabilities	'
	Description	Balance at		Unrealized			Balance at
		December 31,		Gain			June 30,
		2013					2014
	Derivative liabilities related to Warrants	$	4,431,871	$	(2,249,988	)	$	2,181,883

Debt_Tables

Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Debt	'
Schedule of Long-term debt and unamortized discount	'
	Balance at December 31, 2013	$	—
	Face value of term loan	15,000,000
	Fair value of warrants and loan costs	(297,134		)
	Accretion of debt discount	—
	Balance at June 30, 2014	$	14,702,866
Schedule of future minimum payments under loan and security agreement	'
	Year Ending December 31,
	2014	$	441,875
	2015	2,936,808
	2016	5,563,640
	2017	5,563,640
	2018	4,295,457
	Total future minimum payments	18,801,420
	Unamortized interest	(3,801,420		)
	Debt discount	(297,134		)
	Total minimum payment	14,702,866
	Current portion	—
	Long-term debt	$	14,702,866

Business_Overview_Basis_of_Pre1

Business Overview, Basis of Presentation and Liquidity (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jul. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Going Concern	'	'	'	'	'	'	'
Cash used in operating activities	'	'	$5,452,145	$3,364,625	'	'	'
Net loss	-1,077,091	-5,270,090	-4,266,887	-6,380,787	'	'	'
Net cash provided by financing activities	'	'	14,422,759	1,207,272	'	'	'
Cash and cash equivalents	$34,673,893	$8,302,290	$34,673,893	$8,302,290	$33,600,000	$25,836,937	$10,819,781

Net_Loss_Per_Share_Details

Net Loss Per Share (Details)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Net Loss Per Share	'	'
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	10,262,660	10,890,555
Employee Stock Option [Member]	'	'
Net Loss Per Share	'	'
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	3,897,249	4,012,710
Warrant [Member]	'	'
Net Loss Per Share	'	'
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	6,302,286	6,796,491
Convertible Preferred Stock [Member]	'	'
Net Loss Per Share	'	'
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	63,125	81,354

Accounting_for_ShareBased_Paym2

Accounting for Share-Based Payments (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stock-based compensation expense	'	'	'	'
Total stock-based compensation expense	$419,487	$347,342	$979,260	$688,817
Research And Development Expense [Member]	'	'	'	'
Stock-based compensation expense	'	'	'	'
Total stock-based compensation expense	166,019	179,892	355,653	302,209
Selling And Marketing Expense [Member]	'	'	'	'
Stock-based compensation expense	'	'	'	'
Total stock-based compensation expense	29,989	24,085	52,670	45,802
General And Administrative Expense [Member]	'	'	'	'
Stock-based compensation expense	'	'	'	'
Total stock-based compensation expense	$223,479	$143,365	$570,937	$340,806

Accounting_for_ShareBased_Paym3

Accounting for Share-Based Payments (Details 2) (USD $)	6 Months Ended	12 Months Ended		6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
			Equity incentive plan 2014 [Member]	Employee Stock Option [Member]	Employee Stock Option [Member]	Employee Stock Option [Member]	Employee Stock Option [Member]	Employee Stock Option [Member]	Employee Stock Option [Member]
						Minimum [Member]	Minimum [Member]	Maximum [Member]	Maximum [Member]
Unrecognized compensation cost	'	'	'	'	'	'	'	'	'
Unrecognized compensation cost	'	'	'	$3,364,401	$3,708,208	'	'	'	'
Weighted-average remaining vesting period for recognition	'	'	'	'3 years	'3 years	'	'	'	'
Weighted average remaining contractual term of outstanding options	'	'	'	'7 years	'	'	'	'	'
Weighted-average assumptions	'	'	'	'	'	'	'	'	'
Risk-free interest rate (as a percent)	'	'	'	'	'	1.46%	0.74%	1.69%	1.48%
Dividend yield (as a percent)	'	'	'	0.00%	0.00%	'	'	'	'
Expected volatility (as a percent)	'	'	'	'	'	74.00%	97.00%	84.00%	100.00%
Expected term	'	'	'	'5 years	'5 years	'	'	'	'
Total Options	'	'	'	'	'	'	'	'	'
Balance outstanding at the beginning of the period (in shares)	'	'	'	4,287,545	'	'	'	'	'
Granted (in shares)	'	'	'	281,870	'	'	'	'	'
Forfeited (in shares)	'	'	'	-672,166	'	'	'	'	'
Balance outstanding at the end of the period (in shares)	'	'	'	3,897,249	'	'	'	'	'
Exercisable at the end of the period (in shares)	'	'	'	2,000,679	'	'	'	'	'
Authorized shares under the plan	'	'	2,500,000	'	'	'	'	'	'
Weighted Average Exercise Price Per Share	'	'	'	'	'	'	'	'	'
Balance outstanding at the beginning of the period (in dollars per share)	'	'	'	$5.18	'	'	'	'	'
Balance outstanding at the end of the period (in dollars per share)	'	'	'	$4.79	'	'	'	'	'
Exercisable at the end of the period (in dollars per share)	'	'	'	$4.88	'	'	'	'	'
Intrinsic Value	'	'	'	'	'	'	'	'	'
Outstanding	'	'	'	929,688	'	'	'	'	'
Exercisable at the end of the period	'	'	'	$576,626	'	'	'	'	'
Warrants and Rights [Roll Forward]	'	'	'	'	'	'	'	'	'
Balance of warrants outstanding at the beginning of the period (in shares)	6,233,483	'	'	'	'	'	'	'	'
Granted (in shares)	85,470	'	'	'	'	'	'	'	'
Forfeited (in shares)	-16,667	'	'	'	'	'	'	'	'
Balance of warrants outstanding at the end of the period (in shares)	6,302,286	6,233,483	'	'	'	'	'	'	'
Weighted Average Exercise Price Per Share	'	'	'	'	'	'	'	'	'
Weighted average exercise price of warrants at the beginning of the period (in dollars per share)	$3.87	'	'	'	'	'	'	'	'
Granted (in dollars per share)	$3.51	'	'	'	'	'	'	'	'
Forfeited (in dollars per share)	$10.80	'	'	'	'	'	'	'	'
Weighted average exercise price of warrants at the end of the period (in dollars per share)	$3.84	$3.87	'	'	'	'	'	'	'
Weighted Average Remaining Contractual Term	'4 years 1 month 6 days	'4 years 6 months	'	'	'	'	'	'	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (Public Offering And Controlled Equity Offering [Member], USD $)	0 Months Ended	6 Months Ended
	Jan. 25, 2013	Jun. 30, 2014
Cantor Fitzgerald And Co [Member]	'	'
Commission as percentage of gross proceeds	3.00%	'
Sales of common stock	'	$0
Maximum [Member]	'	'
Aggregate initial offering price	150,000,000	'
Maximum [Member] | Cantor Fitzgerald And Co [Member]	'	'
Aggregate initial offering price	30,000,000	'

Asset_Purchase_Agreement_Detai

Asset Purchase Agreement (Details) (Multi Gen Diagnostics Inc [Member], USD $)	1 Months Ended
	Feb. 29, 2012	Feb. 01, 2012
	item
Merger and asset purchase activities	'	'
Issuance of common stock pursuant to acquisitions	$187,500	'
Number of intangible assets to which purchase price would be allocated	1	'
Fair value of the contingent consideration	'	0
Maximum [Member]	'	'
Merger and asset purchase activities	'	'
Consideration to be paid in common stock and cash upon the achievement of specific sales and earnings targets	'	$3,700,000
Restricted Stock [Member]	'	'
Merger and asset purchase activities	'	'
Common stock issued in connection with an asset purchase agreement (in shares)	125,000	'

Derivative_Financial_Instrumen2

Derivative Financial Instruments - Warrants (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Changes in the Company's derivative financial instruments liability balance	'	'	'	'
Balance of warrants outstanding at the beginning of the period (in shares)	'	'	6,233,483	'
Balance of warrants outstanding at the end of the period (in shares)	6,302,286	'	6,302,286	'
Balance of derivative financial instruments liability at the beginning of the period	'	'	$4,431,871	'
Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations	-2,217,142	2,895,310	-2,249,988	1,616,168
Balance of derivative financial instruments liability at the end of the period	2,181,883	'	2,181,883	'
Warrant [Member] | Black Scholes Option Pricing Method [Member]	'	'	'	'
Range of assumptions used to determine the fair value of warrants	'	'	'	'
Dividend yield (as a percent)	'	'	0.00%	0.00%
Changes in the Company's derivative financial instruments liability balance	'	'	'	'
Balance of warrants outstanding at the beginning of the period (in shares)	'	'	1,013,961	'
Balance of warrants outstanding at the end of the period (in shares)	1,013,961	'	1,013,961	'
Balance of derivative financial instruments liability at the beginning of the period	'	'	4,431,871	'
Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations	'	'	-2,249,988	'
Balance of derivative financial instruments liability at the end of the period	$2,181,883	'	$2,181,883	'
Warrant [Member] | Black Scholes Option Pricing Method [Member] | Minimum [Member]	'	'	'	'
Range of assumptions used to determine the fair value of warrants	'	'	'	'
Estimated fair value of Trovagene common stock (in dollars per share)	'	'	$3.50	$6.26
Expected warrant term	'	'	'4 years 6 months	'4 months
Risk-free interest rate (as a percent)	'	'	1.62%	0.04%
Expected volatility (as a percent)	'	'	74.00%	97.00%
Warrant [Member] | Black Scholes Option Pricing Method [Member] | Maximum [Member]	'	'	'	'
Range of assumptions used to determine the fair value of warrants	'	'	'	'
Estimated fair value of Trovagene common stock (in dollars per share)	'	'	$5.73	$6.99
Expected warrant term	'	'	'4 years 9 months 18 days	'5 years 9 months 18 days
Risk-free interest rate (as a percent)	'	'	1.73%	1.41%
Expected volatility (as a percent)	'	'	83.00%	100.00%

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Liabilities:	'	'
Derivative liabilities related to warrants	$2,181,883	$4,431,871
Fair Value Measurements Recurring [Member] | Fair Value Inputs Level1 [Member]	'	'
Assets:	'	'
Money market fund	20,181,958	25,703,330
Total Assets	20,181,958	25,703,330
Fair Value Measurements Recurring [Member] | Fair Value Inputs Level3 [Member]	'	'
Liabilities:	'	'
Derivative liabilities related to warrants	2,181,883	4,431,871
Total Liabilities	2,181,883	4,431,871
Fair Value Measurements Recurring [Member] | Estimate Of Fair Value Fair Value Disclosure [Member]	'	'
Assets:	'	'
Money market fund	20,181,958	25,703,330
Total Assets	20,181,958	25,703,330
Liabilities:	'	'
Derivative liabilities related to warrants	2,181,883	4,431,871
Total Liabilities	$2,181,883	$4,431,871

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (Warrant [Member], USD $)	6 Months Ended
	Jun. 30, 2014
Warrant [Member]	'
Reconciliation of the beginning and ending balances	'
Balance at the beginning of the period	$4,431,871
Unrealized gain	-2,249,988
Balance at the end of the period	$2,181,883

Debt_Details

Debt (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013
			Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Line Of Credit [Member]	Line Of Credit [Member]
			item	item	Minimum [Member]	Maximum [Member]
Debt	'	'	'	'	'	'	'	'
Maximum borrowing capacity of credit facility	'	'	'	'	'	'	'	$1,000,000
Amount borrowed included in current liabilities	'	198,166	'	'	'	'	'	'
Amount borrowed, long-term liabilities	14,702,866	322,998	'	'	'	'	'	'
Fixed interest rate to determine variable interest (as a percent)	'	'	'	'	'	'	5.00%	'
Variable spread over U.S. Treasury Note rate of interest (as a percent)	'	'	'	'	'	'	4.60%	'
Period for payment of principal and interest after date of advances	'	'	'	'	'	'	'30 months	'
Interest expenses recorded	'	'	'	3,000	'	'	61,000	'
Face value of term loan	'	'	15,000,000	15,000,000	'	'	'	'
Number of banks, with which agreement is entered	'	'	2	2	'	'	'	'
Interest rate (as a percent)	'	'	7.07%	7.07%	'	'	'	'
Number of common shares that can be purchased upon exercise of warrant	'	'	85,470	85,470	'	'	'	'
Exercise price of warrants (in dollars per share)	'	'	3.51	3.51	'	'	'	'
Exercisable term	'	'	'10 years	'	'	'	'	'
Value of warrants recorded as debt discount and additional paid in capital	235,857	'	235,857	235,857	'	'	'	'
Pre-payment fees (as a percent)	'	'	'	'	1.00%	3.00%	'	'
Amortized portion of final fee upon repayment	'	'	'	1,050,000	'	'	'	'
Long term debt and unamortized discount	'	'	'	'	'	'	'	'
Face value of term loan	'	'	15,000,000	15,000,000	'	'	'	'
Fair value of warrants and loan costs	'	'	'	-297,134	'	'	'	'
Ending balance	'	'	14,702,866	14,702,866	'	'	'	'
Future minimum payments	'	'	'	'	'	'	'	'
2014	'	'	441,875	441,875	'	'	'	'
2015	'	'	2,936,808	2,936,808	'	'	'	'
2016	'	'	5,563,640	5,563,640	'	'	'	'
2017	'	'	5,563,640	5,563,640	'	'	'	'
2018	'	'	4,295,457	4,295,457	'	'	'	'
Total future minimum payments	'	'	18,801,420	18,801,420	'	'	'	'
Unamortized interest	'	'	-3,801,420	-3,801,420	'	'	'	'
Debt discount	'	'	-297,134	-297,134	'	'	'	'
Total minimum payment	'	'	14,702,866	14,702,866	'	'	'	'
Long-term debt	'	'	$14,702,866	$14,702,866	'	'	'	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	0 Months Ended		6 Months Ended
	14-May-14	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
	sqft	sqft	Minimum [Member]	Maximum [Member]
Lease Agreements	'	'	'	'
Area under lease (in square feet)	'	8,300	'	'
Monthly rental rate	'	'	$18,300	$20,000
Increase in leased space	4,751	'	'	'
Increase in monthly rent	$10,500	'	'	'

Commitments_and_Contingencies_1

Commitments and Contingencies (Details 2) (USD $)	3 Months Ended		6 Months Ended				1 Months Ended	6 Months Ended		0 Months Ended	2 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	8-May-14	Jun. 30, 2014
					Research And Development Arrangement [Member]	Research And Development Arrangement [Member]	Research And Development Arrangement [Member]	Research And Development Arrangement [Member]	Research And Development Arrangement [Member]	Patent Assignment And License Agreement [Member]	Patent Assignment And License Agreement [Member]
					University Of Texas M D Anderson Cancer Center [Member]	Perkin Elmer Health Sciences Inc [Member]	Illumina Inc [Member]	University Of Southern California [Member]	U S Oncology Research L L C [Member]	Gen Signia I P Ltd [Member]	Gen Signia I P Ltd [Member]
Commitments and contingencies	'	'	'	'	'	'	'	'	'	'	'
Amount committed to be paid	'	'	'	'	$266,000	'	'	$232,000	$270,000	'	'
Research and development expense	1,397,173	943,849	2,839,694	1,746,094	204,000	90,000	'	5,000	32,000	'	'
Receipt of milestone payments	'	'	'	'	'	90,000	'	'	'	'	'
Period of termination of agreement, after completion of the research plan	'	'	'	'	'	'	'30 days	'	'	'	'
Period of termination of agreement, on its anniversary unless extended by mutual written agreement	'	'	'	'	'	'	'1 year	'	'	'	'
Milestone Payment to be Received Under Patent Assignment and License Agreement	'	'	'	'	'	'	'	'	'	6,500,000	'
Threshold Limit of Net Sales Revenue to Receive Milestone Payments	'	'	'	'	'	'	'	'	'	150,000,000	'
License and Services Revenue	10,000	'	10,000	'	'	'	'	'	'	'	10,000
License Costs	'	'	'	'	'	'	'	'	'	'	$0